<?xml version="1.0" encoding="UTF-8"?>
<p id="par0235">Using corticosteroids to treat severe pneumonia due to COVID-19 is still controversial. The WHO recommends against the routine use of corticosteroids in these patients [
 <xref rid="bib0060" ref-type="bibr">12</xref>]. Data from clinical trials are widely variable in terms of participants included and results reported, thatâ€™s why clinical judgment should be based on a case-by-case approach. Delayed viral clearance and infection susceptibility are two major concerns that come with corticosteroid usage in COVID-19 patients [
 <xref rid="bib0035" ref-type="bibr">7</xref>,
 <xref rid="bib0225" ref-type="bibr">45</xref>,
 <xref rid="bib0345" ref-type="bibr">69</xref>]. In a recent release, the Surviving Sepsis Campaign has suggested systemic corticosteroid administration for ARDS adult patients with COVID-19 who are mechanically ventilated. On the other hand, recommends against corticosteroid use in adults without ARDS [
 <xref rid="bib0335" ref-type="bibr">67</xref>]. Five randomized controlled trials investigating methylprednisolone in COVID-19 patients are also currently registered [
 <xref rid="bib0190" ref-type="bibr">38</xref>].
</p>
